Evolus Q3 revenue $26.7M (+58% YoY); record sales; initiates extra-strength Jeuveau Phase II

Evolus, Inc.

2021-Q3 EPS reported -$0.60 revenue$65,016,000

U.S. net revenue of $26.7M, up 58% YoY; total net revenue up 51% to $26.7M.
GAAP operating loss $19.1M vs. $8.8M YoY; non-GAAP operating loss $14.3M vs. $6.5M.
Cash $107.8M at Sept 30, down from $131.7M due to $15M milestone payment.
Initiated Phase II for extra-strength Jeuveau; first patient expected Q1 2022, completion 1H 2023.
Accounts purchasing Jeuveau increased by 500 to >6,500; loyalty program doubled to 240,000 registrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.